OncRef

Clinical Trial: NCT05720130

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:AdvanCell Pty Limited
Information Provided By:AdvanCell Pty Limited
Last Update Posted:2026-02-20

Study Overview

Brief Summary

This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of [212Pb]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of [212Pb]Pb-ADVC001 at the RP2 doses in 3 participant groups.

Official Title

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Conditions

Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

Intervention / Treatment

  • Drug: [²¹²Pb]Pb-ADVC001 (Phase 1b)
  • Drug: [²¹²Pb]Pb-ADVC001 (Phase 2a)

Other Study ID Numbers

  • PSMA-AC-01

Start Date (Actual)

2023-03-15

Primary Completion Date (Estimated)

2029-01-31

Study Completion Date (Estimated)

2029-06-01

Enrollment (Estimated)

100

Study Type

Interventional

Phase

Phase 1, Phase 2